Early diagnosis and precise treatment of hepatocellular carcinoma

Wenxing Zhao

doi:10.1051/e3sconf/202127103012

All issues

Volume 271 (2021)

E3S Web Conf., 271 (2021) 03012

References

Open Access

Issue		E3S Web Conf. Volume 271, 2021 2021 2^nd International Academic Conference on Energy Conservation, Environmental Protection and Energy Science (ICEPE 2021)


Article Number		03012
Number of page(s)		4
Section		Research on Energy Chemistry and Chemical Simulation Performance
DOI		https://doi.org/10.1051/e3sconf/202127103012
Published online		15 June 2021

R. Salem, R.J. Lewandowski, Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604 [CrossRef] [PubMed] [Google Scholar]
Zeng H., Chen W., Zheng R., Zhang S., Ji J.S., Zou X., et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5): e555–67. [CrossRef] [PubMed] [Google Scholar]
Zhou M., Wang H., Zeng X., et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2020 Jul 4;396 (10243):26]. Lancet. 2019; 394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-1 [CrossRef] [Google Scholar]
Medavaram S., Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [CrossRef] [PubMed] [Google Scholar]
Kumar V., Abbas A.K., Aster J.C., editors. Robbins & Contran. Pathologic Basis of Diseases. 9th ed. Philadelphia: Elsevier; 2014. [Google Scholar]
Clavien P.A., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22. [CrossRef] [PubMed] [Google Scholar]
Colli A., Fraquelli M., Casazza G., Massironi S., Colucci A., Conte D., Duca P. Accuracy of ultrasonography, spiral C.T., magnetic resonance, and alpha fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101:513–523. [CrossRef] [PubMed] [Google Scholar]
Li D., Mallory T., Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.[J]. Clinica Chimica Acta, 2001, 313(1-2):15–19. [CrossRef] [Google Scholar]
Raphaël Saffroy, Pham, P., Maâmar Reffas, et al. New perspectives and strategy research biomarkers for hepatocellular carcinoma[J]. Clinical Chemistry & Laboratory Medicine, 2007, 45(9):1169–1179. [Google Scholar]
Matouk I. J., Degroot N., Mezan S., et al. The H19 Non-Coding RNA Is Essential for Human Tumor Growth[J]. Plos One, 2012, 2. [Google Scholar]
Braconi, Kogure, Valeri, et al. Microrna-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.[J]. Oncogene, 2011. [PubMed] [Google Scholar]
Ming-chun, Lai, Zhe, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation[J]. Medical Oncology, 2012. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.

[1] R. Salem, R.J. Lewandowski, Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604 [CrossRef] [PubMed] [Google Scholar]

[2] Zeng H., Chen W., Zheng R., Zhang S., Ji J.S., Zou X., et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5): e555–67. [CrossRef] [PubMed] [Google Scholar]

[3] Zhou M., Wang H., Zeng X., et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2020 Jul 4;396 (10243):26]. Lancet. 2019; 394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-1 [CrossRef] [Google Scholar]

[4] Medavaram S., Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [CrossRef] [PubMed] [Google Scholar]

[5] Kumar V., Abbas A.K., Aster J.C., editors. Robbins & Contran. Pathologic Basis of Diseases. 9th ed. Philadelphia: Elsevier; 2014. [Google Scholar]

[6] Clavien P.A., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22. [CrossRef] [PubMed] [Google Scholar]

[7] Colli A., Fraquelli M., Casazza G., Massironi S., Colucci A., Conte D., Duca P. Accuracy of ultrasonography, spiral C.T., magnetic resonance, and alpha fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101:513–523. [CrossRef] [PubMed] [Google Scholar]

[8] Li D., Mallory T., Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.[J]. Clinica Chimica Acta, 2001, 313(1-2):15–19. [CrossRef] [Google Scholar]

[9] Raphaël Saffroy, Pham, P., Maâmar Reffas, et al. New perspectives and strategy research biomarkers for hepatocellular carcinoma[J]. Clinical Chemistry & Laboratory Medicine, 2007, 45(9):1169–1179. [Google Scholar]

[10] Matouk I. J., Degroot N., Mezan S., et al. The H19 Non-Coding RNA Is Essential for Human Tumor Growth[J]. Plos One, 2012, 2. [Google Scholar]

[11] Braconi, Kogure, Valeri, et al. Microrna-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.[J]. Oncogene, 2011. [PubMed] [Google Scholar]

[12] Ming-chun, Lai, Zhe, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation[J]. Medical Oncology, 2012. [Google Scholar]